Grifols's Subsidiary Biotest Forecasts Approximately $1B In Revenue From Sales In The U.S. Of Its Intravenous Immunoglobulin Yimmugo During The Next Seven Years, Following Recent FDA Approval To Treat Primary Immunodeficiencies
Grifols's Subsidiary Biotest Forecasts Approximately $1B In Revenue From Sales In The U.S. Of Its Intravenous Immunoglobulin Yimmugo During The Next Seven Years, Following Recent FDA Approval To Treat Primary Immunodeficiencies
基立福的子公司Biotest预计，在近7年内，其静脉免疫球蛋白Yimmugo在美国销售的营业收入将达到约10亿美元，此前该产品已获得FDA批准用于治疗原发性免疫缺陷病。
- Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025
- 基立福集团旗下的Biotest公司预计将于2025年第一季度在美国推出其最近获FDA批准的静脉免疫球蛋白。
- Yimmugo will be distributed by Kedrion in the U.S. as part of a broader Group channel strategy, with Grifols focusing on continued growth of its current portfolio for this market
- Yimmugo将由Kedrion在美国分销，作为更广泛集团渠道策略的一部分，而基立福则专注于继续发展其当前市场的产品组合。
- It adds to Grifols' strong franchise of intravenous and subcutaneous immunoglobulins to meet growing patient demand for these therapeutics
- 这将增强基立福在静脉和皮下免疫球蛋白领域的强劲知名度，以满足不断增长的患者对这些治疗的需求。
- Yimmugo will be followed by other proteins in the pipeline, including fibrinogen and trimodulin, both in late-stage development
- Yimmugo将跟进其他正在研发中的蛋白质，包括晚期开发的纤维蛋白原和三联素。